Unicycive Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell UNCY and other ETFs, options, and stocks.About UNCY
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220.
CEOShalabh Gupta
CEOShalabh Gupta
Employees22
Employees22
HeadquartersLos Altos, California
HeadquartersLos Altos, California
Founded2016
Founded2016
Employees22
Employees22
UNCY Key Statistics
Market cap131.42M
Market cap131.42M
Price-Earnings ratio-1.88
Price-Earnings ratio-1.88
Dividend yield—
Dividend yield—
Average volume393.91K
Average volume393.91K
High today$6.35
High today$6.35
Low today$5.87
Low today$5.87
Open price$6.09
Open price$6.09
Volume509.19K
Volume509.19K
52 Week high$11.00
52 Week high$11.00
52 Week low$3.71
52 Week low$3.71
Stock Snapshot
As of today, Unicycive Therapeutics(UNCY) shares are valued at $6.28. The company's market cap stands at 131.42M, with a P/E ratio of -1.88.
On 2026-01-09, Unicycive Therapeutics(UNCY) stock moved within a range of $5.87 to $6.35. With shares now at $6.28, the stock is trading +7.0% above its intraday low and -1.1% below the session's peak.
Trading volume for Unicycive Therapeutics(UNCY) stock has reached 509.19K, versus its average volume of 393.91K.
The stock's 52-week range extends from a low of $3.71 to a high of $11.00.
The stock's 52-week range extends from a low of $3.71 to a high of $11.00.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own UNCY. This list is generated using Robinhood data, and it’s not a recommendation.